Executives seek “skin in the game” despite signs of a stock market cooldown.
Written by Nikkei Asia
Published on
7 May 2026
3 mins read
Global pharmaceutical executives are hungry for more deals with Chinese biotechnology companies after a record year, even as a stock market boom shows signs of cooling down.
Such deals allow Chinese firms to profit while minimising capital outlays, but also carry risks, law firm says.
China biotech remains a market bright spot with strong growth, driven by out-licensing, efficiency improvements and cost control.
‘We are on an upcycle in the industry and sentiment is very strong,’ Xufunds Investment fund manager Wang Chen says.
After years of buying licences for foreign-made medicines, Chinese biotech firms are now profiting handsomely from their own…
Strong growth momentum and global push expected to continue.
First payment from US$6 billion deal with Gregory Verdine’s DoveTree swings the Hong Kong-listed firm to a net profit.
UCB to acquire maker of antibody treatments for autoimmune diseases
